Drugs Made In America Acquisition (DMAAR) Cash & Equivalents (2024 - 2025)
Drugs Made In America Acquisition (DMAAR) reported Cash & Equivalents of $6137.0 for Q4 2025, up 354.26% on a YoY basis from $1351.0 in Q4 2024, and up 755.93% quarter-over-quarter from $717.0 in Q3 2025.
Drugs Made In America Acquisition (DMAAR) Cash & Equivalents (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition has reported Cash & Equivalents for 2 years, with the latest figure at $6137.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 354.26% year-over-year to $6137.0; the trailing twelve-month figure through Dec 2025 stood at $6137.0 (up 354.26% YoY), and the FY2025 full-year result was $6137.0, up 354.26% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $6137.0, up from $717.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $6137.0 in Q4 2025, with the low at $717.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | 1.47 Mn |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - | 209,016.00 |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - | 28,828.00 |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - | 112,660.00 |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - | 167,798.00 |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - | 553,972.00 |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - | 521,352.00 |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - | 56,403.00 |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - | 1.45 Mn |
| 10 | Drugs Made In America Acquisition | - | - | - | 6,137.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,137.00 |
| Sep 30, 2025 | 717.00 |
| Jun 30, 2025 | 822.00 |
| Mar 31, 2025 | 923.00 |
| Dec 31, 2024 | 1,351.00 |